Worth assessing the PTX announcement today released their AML 1b/2 first cohort results, no toxicity and moving forward to next dosage. Promising. Further results due for parallel but seperate trials for recuring ovarian and breast cancer patients. The MC of PTX at 18 mill wilh solid cash in hand to conclude current trials creates a potential multi opportunity for SHers and the very real potential that the drugs under trial can make a real difference to future patients. Early days yet but can't be ignored.
